Browsing Tag
European Society of Cardiology
5 posts
CRISPR Therapeutics advances one-time cardiovascular strategy as CTX310 lipid reductions persist for a year
CTX310 sustains deep lipid reductions for one year as CRISPR Therapeutics expands its cardiovascular gene-editing strategy. See what comes next.
Myqorzo could expand across the HCM spectrum after Cytokinetics delivers pivotal ACACIA-HCM results
Cytokinetics plans an FDA filing after aficamten succeeds in non-obstructive HCM. See what ACACIA-HCM could mean for Myqorzo growth.
AstraZeneca (AZN) shares fall as Wainua Phase III trial miss dents ATTR-CM growth hopes
Read how AstraZeneca’s Wainua trial miss reshapes AZN stock sentiment, ATTR-CM competition and its 2030 growth story after July 9.
Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe
Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe.
Alnylam Pharmaceuticals (NASDAQ: ALNY) to launch global Phase 3 trial of RNAi therapy zilebesiran in high-risk hypertension patients
Alnylam Pharmaceuticals (NASDAQ: ALNY) moves its RNAi drug zilebesiran into a global Phase 3 trial for hypertension after ESC 2025 data showed sustained blood pressure reductions.